Cited by 353Pancreatic and Hepatic Oncology ResearchBreast Cancer Treatment StudiesCholangiocarcinoma and Gallbladder Cancer Studies

The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.

GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer

Open access

O’Kane, Grainne M., Grünwald, Barbara T., Jang, Gun-Ho, Masoomian, Mehdi, Picardo, Sarah, Grant, Robert C., Denroche, Robert E., Zhang, Amy, Wang, Yifan, Miller, Jessica K., Lam, Bernard, Krzyzanowski, Paul M., Lungu, Ilinca M., Bartlett, John M.S., Peralta, Melanie, Vyas, Foram, Khokha, Rama, Biagi, James, Chadwick, Dianne, Ramotar, Stephanie, Hutchinson, Shawn, Dodd, Anna, Wilson, Julie M., Notta, Faiyaz, Zogopoulos, George, Gallinger, Steven, Knox, Jennifer J., Fischer, Sandra E.·2020·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-19-3724

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: To determine the impact of basal-like and classical subtypes in advanced pancreatic ductal adenocarcinoma (PDAC) and to explore GATA6 expression as a surrogate biomarker. Experimental Design: Within the COMPASS trial, patients proceeding to chemotherapy for advanced PDAC undergo tumor biopsy for RNA-sequencing (RNA-seq). Overall response rate (ORR) and overall survival (OS) were stratified by subtypes and according to chemotherapy received. Correlation of GATA6 with the subtypes using gene expression profiling, in situ hybridization (ISH) was explored. Results: Between December 2015 and May 2019, 195 patients (95%) had enough tissue for RNA-seq; 39 (20%) were classified as basal-like and 156 (80%) as classical. RECIST response data were available for 157 patients; 29 basal-like and 128 classical where the ORR was 10% versus 33%, respectively (P = 0.02). In patients with basal-like tumors treated with modified FOLFIRINOX (n = 22), the progression rate was 60% compared with 15% in classical PDAC (P = 0.0002). Median OS in the intention-to-treat population (n = 195) was 9.3 months for classical versus 5.9 months for basal-like PDAC (HR, 0.47; 95% confidence interval, 0.32–0.69; P = 0.0001). GATA6 expression by RNA-seq highly correlated with the classifier (P < 0.001) and ISH predicted the subtypes with sensitivity of 89% and specificity of 83%. In a multivariate analysis, GATA6 expression was prognostic (P = 0.02). In exploratory analyses, basal-like tumors, could be identified by keratin 5, were more hypoxic and enriched for a T-cell–inflamed gene expression signature. Conclusions: The basal-like subtype is chemoresistant and can be distinguished from classical PDAC by GATA6 expression. See related commentary by Collisson, p. 4715

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-3724

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Cancer statistics, 2016
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
The control of the false discovery rate in multiple testing under dependency
Benjamini, Y., & Yekutieli, D. (2001) · The Annals of Statistics · doi:10.1214/aos/1013699998 · Cited by 10,490
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712

Show all 39 references

Sorted by citations

Items 101–200 of 353

Advances in the management of pancreatic ductal adenocarcinoma
O'Kane, G. M., Ladak, F., & Gallinger, S. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.201450 · Cited by 23
Self-citation
HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells
Ewers, K. M., Patil, S., Kopp, W., Thomale, J., Quilitz, T., Magerhans, A., Wang, X., Heßmann, E., & Dobbelstein, M. (2021) · Cancers · doi:10.3390/cancers13246163 · Cited by 24
Preoperative therapy for pancreatic adenocarcinoma—precision beyond anatomy
Seo, Y. D., & Katz, M. H. G. (2022) · Cancer · doi:10.1002/cncr.34273 · Cited by 24
Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis
Usón, P. L. S., Carvalho, L., Fernandes, M. L. C., Botrus, G., Martins, R. D. S., da Silva, E. F., dos Santos, S. S. M. B., Taniwaki, L., Taranto, P., Dutra, A. C. P., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-17743-6 · Cited by 24
Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies
Kuznetsova, A. V., Попова, О. П., Panchenkov, D. N., Dyuzheva, Т. G., & Aa, I. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00886-1 · Cited by 24
Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction
Matsumoto, K., Fujimori, N., Ichihara, K., Takeno, A., Murakami, M., Ohno, A., Kakehashi, S., Teramatsu, K., Ueda, K., Nakata, K., et al. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02103-0 · Cited by 24
MicroRNA-143 as a potential tumor suppressor in cancer: An insight into molecular targets and signaling pathways.
Asghariazar, V., Kadkhodayi, M., Sarailoo, M., Jolfayi, A. G., & Baradaran, B. (2023) · Pathology, Research and Practice · doi:10.1016/j.prp.2023.154792 · Cited by 20
Nuclear Dynamics and Chromatin Structure: Implications for Pancreatic Cancer
Flores, L. F., Tader, B. R., Tolosa, E. J., Sigafoos, A. N., Marks, D. L., & Fernández-Zapico, M. E. (2021) · Cells · doi:10.3390/cells10102624 · Cited by 23
Post‐operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A , p53, and SMAD4 expression
Masugi, Y., Takamatsu, M., Tanaka, M., Hara, K., Inoue, Y., Hamada, T., Suzuki, T., Arita, J., Hirose, Y., Kawaguchi, Y., et al. (2023) · The Journal of Pathology: Clinical Research · doi:10.1002/cjp2.323 · Cited by 23
Targeting the Stroma in the Management of Pancreatic Cancer
Edwards, P., Kang, B. W., & Chau, I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.691185 · Cited by 22
Hypoxia at 3D organoid establishment selects essential subclones within heterogenous pancreatic cancer
Kumano, K., Nakahashi, H., Louphrasitthiphol, P., Kuroda, Y., Miyazaki, Y., Shimomura, O., Hashimoto, S., Akashi, Y., Mathis, B. J., Kim, J., et al. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1327772 · Cited by 21
GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery
van Eijck, C. W. F., Real, F. X., Malats, N., Vadgama, D., van den Bosch, T. P. P., Doukas, M., van Eijck, C. H. J., & Mustafa, D. A. M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101557 · Cited by 21
Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort
Lansbergen, M. F., Dings, M. P. G., Manoukian, P., Sarasqueta, A. F., Waasdorp, C., Hooijer, G. K. J., Verheij, J., Köster, J., Zwijnenburg, D. A., Wilmink, J. W., et al. (2024) · Translational research · doi:10.1016/j.trsl.2024.08.002 · Cited by 21
RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features
Archibugi, L., Ruta, V., Panzeri, V., Redegalli, M., Testoni, S. G. G., Petrone, M. C., Rossi, G., Falconi, M., Reni, M., Doglioni, C., et al. (2020) · Cells · doi:10.3390/cells9122561 · Cited by 20
Application of single-cell sequencing technologies in pancreatic cancer
Mannarapu, M., Dariya, B., & Bandapalli, O. R. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04095-4 · Cited by 20
Emerging insights into lineage plasticity in pancreatic cancer initiation, progression, and therapy resistance
Zhang, X., Du, Y., Behrens, A., & Lan, L. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.07.002 · Cited by 19
Deconstructing Pancreatic Cancer Using Next Generation-Omic Technologies–From Discovery to Knowledge-Guided Platforms for Better Patient Management
Schreyer, D., Neoptolemos, J. P., Barry, S. T., & Bailey, P. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.795735 · Cited by 19
Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer
Iovanna, J. (2021) · Translational Oncology · doi:10.1016/j.tranon.2020.100965 · Cited by 18
Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges
Srilatha, M., Malla, R. R., Adem, M. P., Foote, J. B., & Nagaraju, G. P. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.002 · Cited by 19
Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival
Bailey, P. J., Zhou, X., An, J., Peccerella, T., Hu, K., Springfeld, C., Büchler, M. W., & Neoptolemos, J. P. (2023) · Function · doi:10.1093/function/zqad011 · Cited by 18
Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancer
Kim, J. S., Park, C. H., Kim, E., Lee, H. S., Lee, J.-Y., Kim, J., Kam, E. H., Nam, S., Chung, M. J., Park, J. Y., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02374-y · Cited by 20
BRAF Δβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability
Lauinger, M., Christen, D., Klar, R. F. U., Roubaty, C., Heilig, C. E., Stumpe, M., Knox, J. J., Radulovich, N., Tamblyn, L., Xie, I. Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade7486 · Cited by 17
Self-citation
The trend toward more target therapy in pancreatic ductal adenocarcinoma
Deiana, C., Agostini, M., Brandi, G., & Giovannetti, E. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2357802 · Cited by 17
Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma
Golesworthy, B., Wang, Y., Tanti, A., Pacis, A., Romero, J. M., Cuggia, A., Domecq, C., Bourdel, G., Denroche, R. E., Jang, G. H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.860767 · Cited by 16
Self-citation
An unbiased high‐throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer
Pan, C., Otsuka, Y., Sridharan, B., Woo, M., Leiton, C. V., Babu, S., Gonçalves, M. T., Kawalerski, R. R., Bai, J. D. K., Chang, D. K.-F., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12743 · Cited by 16
Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer
AlMasri, S. S., Zenati, M. S., Hammad, A. Y., Nassour, I., Liu, H., Hogg, M. E., Zeh, H. J., Boone, B. A., Bahary, N., Singhi, A. D., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.18355 · Cited by 16
Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom‐up approach
Hilmi, M., Delecourt, F., Raffenne, J., Bourega, T. A., Dusetti, N., Iovanna, J., Blum, Y., Richard, M., Neuzillet, C., Couvelard, A., et al. (2025) · The Journal of Pathology · doi:10.1002/path.6398 · Cited by 15
Sirtuin 6 is required for the integrated stress response and resistance to inhibition of transcriptional cyclin-dependent kinases
Kartha, N., Gianopulos, J. E., Schrank, Z., Cavender, S. M., Dobersch, S., Kynnap, B. D., Wallace-Povirk, A., Wladyka, C. L., Santana, J. F., Kim, J. C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9674 · Cited by 15
Self-citation
The role of molecular testing in pancreatic cancer
Zhen, D. B., Safyan, R. A., Konick, E. Q., Nguyen, R., Pritchard, C. C., & Chiorean, E. G. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231171456 · Cited by 16
Emerging Prognostic and Predictive Factors in Pancreatic Cancer
Karamitopoulou, E. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100328 · Cited by 16
Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma
Shibayama, T., Hayashi, A., Masao, T., Kitahama, K., Ho, Y.-J., Kato, K., Yamada, T., Kawamoto, S., Kambayashi, K., Ochiai, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-65900-w · Cited by 15
Pancreatic ductal adenocarcinoma in the era of precision medicine
Zheng-Lin, B., & O'Reilly, E. M. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.01.005 · Cited by 16
Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic
Gil, Y. R., Sánchez, P. J., Velasco, R. M., García, A. G., & Lobo, V. J. S.-A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042077 · Cited by 18
Models of pancreatic ductal adenocarcinoma
Dennaoui, R., Shrestha, H., & Wagner, K. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09989-9 · Cited by 19
Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
Hoare, O., Fraunhoffer, N. A., Kaoutari, A. E., Gayet, O., Bigonnet, M., Roques, J., Nicolle, R., McGUCKIN, C. P., Forraz, N., Sohier, E., et al. (2021) · Cancers · doi:10.3390/cancers13102473 · Cited by 17
Mitochondrial fitness and cancer risk
Kossenkov, A. V., Milcarek, A. T., Notta, F., Jang, G.-H., Wilson, J. M., Gallinger, S., Zhou, D. C., Ding, L., Ghosh, J. C., Perego, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273520 · Cited by 14
Self-citation
Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities
Wang, Y., Lakoma, A., & Zogopoulos, G. (2020) · Genes · doi:10.3390/genes11091098 · Cited by 14
Self-citation
Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma
Liu, P., Jacques, J., & Hwang, C. (2024) · Epigenomes · doi:10.3390/epigenomes8040041 · Cited by 13
Pancreatic cancer
Roth, S., Apte, M. V., Balachandran, V. P., Biffi, G., Conroy, T., Cukierman, E., Dotan, E., Esposito, I., Grünwald, B. T., Klauß, M., et al. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00699-6 · Cited by 19
Self-citation
The Role of lncRNAs in the Stem Phenotype of Pancreatic Ductal Adenocarcinoma
Meléndez-Zajgla, J., & Maldonado, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126374 · Cited by 13
Personalized treatment in localized pancreatic cancer
Neoptolemos, J. P., Hu, K., Bailey, P. J., Springfeld, C., Cai, B., Miao, Y., Michalski, C. W., Carvalho, C. T., Hackert, T., & Büchler, M. W. (2023) · European surgery. Supplement/European surgery · doi:10.1007/s10353-023-00814-x · Cited by 13
Clinical Evaluation of the Pancreatic Cancer Microenvironment: Opportunities and Challenges
Szczepanski, J. M., Rudolf, M. A., & Shi, J. (2024) · Cancers · doi:10.3390/cancers16040794 · Cited by 15
Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma
Naso, J. R., Topham, J. T., Karasinska, J. M., Lee, M. K. C., Kalloger, S. E., Wong, H., Nelson, J., Moore, R. A., Mungall, A. J. J., Jones, S. J. M., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3695 · Cited by 13
Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma
Li, Y., Hong, Y. K., Wang, X., Pandit, H., Zheng, Q., Yu, Y., Shi, X., Chen, Y., Tan, M., Pulliam, Z., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1430 · Cited by 14
Organoids at the PUB: The Porcine Urinary Bladder Serves as a Pancreatic Niche for Advanced Cancer Modeling
Melzer, M. K., Breunig, M., Arnold, F., Wezel, F., Azoitei, A., Roger, É., Krüger, J., Merkle, J., Schütte, L. D., Resheq, Y. J., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102345 · Cited by 15
Pathology and Molecular Characteristics of Pancreatic Cancer
Kearney, J. F., Adsay, V. N., & Yeh, J. J. (2021) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2021.06.003 · Cited by 15
Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Beatty, G. L., Delman, D., Yu, J., Liu, M., Li, J. H., Zhang, L., Lee, J. W., Chang, R. B., Bahary, N., Kennedy, E. P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0535 · Cited by 13
Purity Independent Subtyping of Tumors (PurIST) Pancreatic Cancer Classifier
Li, Y., Merker, J. D., Kshatriya, R., Trembath, D. G., Morrison, A. B., Kuhlers, P. C., Rashid, N. U., Yeh, J. J., & Gulley, M. L. (2024) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2024.07.002 · Cited by 12
HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma
Yamamoto, N., Dobersch, S., Loveless, I. M., Samraj, A. N., Jang, G. H., Haraguchi, M., Kang, L., Ruzinova, M. B., Vij, K. R., Mudd, J. L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2200 · Cited by 12
Self-citation
Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms Reveals Divergent Indolent and Malignant States
Iyer, M. K., Fletcher, A. A., Okoye, J. O., Shi, C., Chen, F., Kanu, E. N., Eckhoff, A. M., Bao, M., di Magliano, M. P., Frankel, T. L., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1529 · Cited by 12
Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials
Lo, W. M., & Zureikat, A. H. (2022) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000874 · Cited by 12
High‐resolution and quantitative spatial analysis reveal intra‐ductal phenotypic and functional diversification in pancreatic cancer
Michiels, E., Madhloum, H., Lint, S. V., Messaoudi, N., Kunda, R., Martens, S., Giron, P., Olsen, C., Lefesvre, P., Dusetti, N., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6212 · Cited by 12
Molecular, metabolic, and histological subtypes of pancreatic ductal adenocarcinoma and its tumor microenvironment: Insights into tumor heterogeneity and clinical implications
Ohara, Y., Liu, H., Moreno, P., Suzuki, S., & Hussain, S. P. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108946 · Cited by 11
Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer
Safyan, R. A., Kim, E., Dekker, E. N., Homs, M. Y. V., Aguirre, A. J., Koerkamp, B. G., & Chiorean, E. G. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438598 · Cited by 12
Organoids, tissue slices and organotypic cultures: Advancing our understanding of pancreatic ductal adenocarcinoma through in vitro and ex vivo models
Aksoy, S. A., Earl, J., Grahovac, J., Karakaş, D., Lencioni, G., Sığırlı, S., & Bijlsma, M. F. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.12.003 · Cited by 11
Epithelial to Mesenchymal Transition as Mechanism of Progression of Pancreatic Cancer: From Mice to Men
Greco, L., Rubbino, F., & Laghi, L. (2022) · Cancers · doi:10.3390/cancers14235797 · Cited by 13
The Relationship between the Expression of GATA4 and GATA6 with the Clinical Characteristics and Prognosis of Resectable Pancreatic Adenocarcinoma
Heredia-Soto, V., Gutiérrez-Sainz, L., Ghanem, I., Guerra, L., Palacios, E., de Uribe, M., Trilla‐Fuertes, L., de Miguel, M., Cejas, P., Medina, L., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020252 · Cited by 11
Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma
Hilmi, M., Cros, J. F., Puleo, F., Augustin, J., Emile, J., Svrcek, M., Hammel, P. R., Arsenijevic, T., Laethem, J. V., Bachet, J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.042 · Cited by 12
DNA methylation‐associated allelic inactivation regulates Keratin 19 gene expression during pancreatic development and carcinogenesis
Krüger, J., Fischer, A., Breunig, M., Allgöwer, C., Schulte, L.-A., Merkle, J., Mulaw, M. A., Okeke, N., Melzer, M. K., Morgenstern, C., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6156 · Cited by 10
GATA6 in pancreatic cancer initiation and progression
Ma, M., An, J., Jiang, T., & Xie, K. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101353 · Cited by 11
Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma?
Skorupan, N., Ghabra, S., Maldonado, J. A., Zhang, Y., & Alewine, C. (2023) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.106 · Cited by 10
Reveal the Heterogeneity in the Tumor Microenvironment of Pancreatic Cancer and Analyze the Differences in Prognosis and Immunotherapy Responses of Distinct Immune Subtypes
Wang, X., Li, L., Yang, Y., Fan, L., Ma, Y., & Mao, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.832715 · Cited by 10
The tumor microenvironment drives transcriptional phenotypes and their plasticity in metastatic pancreatic cancerPreprint
Raghavan, S., Winter, P. S., Navia, A. W., Williams, H. L., DenAdel, A., Kalekar, R. L., Galvez-Reyes, J., Lowder, K. E., Mulugeta, N., Raghavan, M. S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.25.256214 · Cited by 10
Molecular Pathology of Pancreatic Cancer
Karamitopoulou, E. (2022) · Cancers · doi:10.3390/cancers14061523 · Cited by 10
Tumor-intrinsic and Cancer-associated Fibroblast Subtypes Independently Predict Outcomes in Pancreatic Cancer
Lee, J. J., Kearney, J. F., Trembath, H. E., Hariharan, A., LaBella, M. E., Kharitonova, E. V., Chan, P., Morrison, A. B., Cliff, A. M., Meyers, M. O., et al. (2024) · Annals of Surgery · doi:10.1097/sla.0000000000006416 · Cited by 9
Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis
Dekker, E. N., Narayan, R. R., Ahmami, M. A., Meddouch, A., Verkolf, E. M. M., Gehrels, A. M., Besselink, M. G., van Eijck, C. H. J., Homs, M. Y. V., Mostert, B., et al. (2024) · British journal of surgery · doi:10.1093/bjs/znae244 · Cited by 9
Self-citation
Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches
Xu, Y., Peng, X. L., East, M. P., McCabe, I. C., Stroman, G. C., Jenner, M. R., Chan, P., Morrison, A. B., Shen, E. C., Hererra, S. G., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1480 · Cited by 9
Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components
Zhao, S., Nicolle, R., Augustin, J., Svrcek, M., de Mestier, L., Corre, D. L., Pietrasz, D., Caliez, O., Cros, J. F., Laurent‐Puig, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1907 · Cited by 9
Orchestration of mesenchymal plasticity and immune evasiveness via rewiring of the metabolic program in pancreatic ductal adenocarcinoma
Hashimoto, A., Handa, H., Hata, S., & Hashimoto, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1005566 · Cited by 9
Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities
Steiner, S., Pliego‐Mendieta, A., Haberecker, M., Hussung, S., Kollár, A., Fritsch, R., Arnold, F. M., Lenggenhager, D. M., Planas‐Paz, L., & Pauli, C. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216650 · Cited by 10
Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
O'Kane, G. M., Grünwald, B. T., Jang, G.-H., Masoomian, M., Picardo, S. L., Grant, R. C., Denroche, R. E., Zhang, A. X. W., Wang, Y., Miller, J. K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1272 · Cited by 9
Self-citation
CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Alcoholic Pancreatitis
Srinivasan, S., Mehra, S., Jinka, S., Bianchi, A., Singh, S. P., Dosch, A. R., Amirian, H., Krishnamoorthy, V., Silva, I. D. C., Patel, M. S., et al. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101606 · Cited by 9
In situ multi-modal characterization of pancreatic cancer reveals tumor cell identity as a defining factor of the surrounding microenvironment
Lyubetskaya, A., Rabe, B. A., Kavran, A. J., Bai, Y., Fisher, A., Font‐Tello, A., Lewin, A. C., Pliner, H. A., Fan, Y., Giampapa, L., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116827 · Cited by 10
Correlation of transcriptional subtypes with a validated CT radiomics score in resectable pancreatic ductal adenocarcinoma
Salinas-Miranda, E., Healy, G. M., Grünwald, B. T., Jain, R., Deniffel, D., O'Kane, G. M., Grant, R. C., Wilson, J. M., Knox, J. J., Gallinger, S., et al. (2022) · European Radiology · doi:10.1007/s00330-022-09057-y · Cited by 7
Self-citation
Dual and triple gene combinations of KRT5 , KRT17 , and S100A2 identify basal‐like subtype of pancreatic ductal adenocarcinoma and correlate with survival outcome
Chen, Q., Chen, Z., Zhang, J., Cai, Y., Wu, S., He, D., Cheng, K., Gu, X., Cai, Y., Wang, X., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202302484rr · Cited by 7
HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity
Dobersch, S., Yamamoto, N., Schutter, A., Cavender, S. M., Robertson, T. M., Kartha, N., Samraj, A. N., Doron, B., Poole, L. A., Wladyka, C. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60129-1 · Cited by 8
Self-citation
Integrative genomic identification of therapeutic targets for pancreatic cancer
Guo, J. A., Gong, D. H., Evans, K. E., Takahashi, K., Jambhale, A. D., Shiau, C., Yu, P. Z., Wang, S., Wu, W., Chugh, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116191 · Cited by 9
Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma
Wenric, S., Sangli, C., Guittar, J. L., Islam, F., Zander, A. D., Hyun, S. W., Davison, J. M., Mayhew, G. M., Beebe, K. D., Beauchamp, K. A., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00197 · Cited by 7
An injury-associated lobular microniche is associated with the classical tumor cell phenotype in pancreatic cancer
Söderqvist, S., Viljamaa, A., Geyer, N., Keller, A., Ruksha, K., Strell, C., Hekmati, N., Niculae, A., Engstrand, J., Sparrelid, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63864-7 · Cited by 7
Cytokeratin 6 identifies basal-like subtypes of pancreatic ductal adenocarcinoma with decreased survival
Lyu, S. I., Krey, T., Damanakis, A. I., Zhao, Y., Bruns, C. J., Schmidt, T., Popp, F., Quaas, A., Knipper, K., the PANCALYZE Study Group, et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04702-5 · Cited by 7
Upregulation of the histone γ-H2AX correlates with worse patient survival and basal-like subtype in pancreatic ductal adenocarcinoma
Knipper, K., Hussein, Y., Simon, A. G., Fretter, C., Damanakis, A. I., Zhao, Y., Bruns, C. J., Schmidt, T., Popp, F., Quaas, A., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05681-x · Cited by 7
Pancreatic cancer: new approaches to drug therapy
Picozzi, V. J. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000000877 · Cited by 7
Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer
Singh, H., Perez, K. J., Wolpin, B. M., & Aguirre, A. J. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01510 · Cited by 7
Characterization of the GATA Transcription Factor Family and Exploration of Their Relevance to Immune Infiltration and Tumor Microenvironment in Pancreatic Cancer
Xu, J., Cheng, K., Lin, H., Han, W., He, T., Nie, X., Sun, Y., Sulidankazha, Q., Reheman, Y., & Chen, Q. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s342741 · Cited by 7
Advances in Surgery and (Neo) Adjuvant Therapy in the Management of Pancreatic Cancer
Liu, M., & Wei, A. C.-C. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.01.004 · Cited by 7
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer
Merz, V., Mangiameli, D., Zecchetto, C., Quinzii, A., Pietrobono, S., Messina, C. G. M., Casalino, S., Gaule, M., Pesoni, C., Vitale, P., et al. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.866173 · Cited by 7
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1
Laethem, J. V., Geboes, K. P., Borbath, I., Macarulla, T. M., Lambert, A., Cassier, P. A., Prenen, H., Mitry, E., Blanc, J., Pilla, L., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102407 · Cited by 6
Minimally invasive determination of pancreatic ductal adenocarcinoma ( PDAC ) subtype by means of circulating cell‐free RNA
Metzenmacher, M., Zaun, G., Trajkovic‐Arsic, M., Cheung, P. F., Reißig, T. M., Schürmann, H., Neuhoff, N. V., O'Kane, G. M., Ramotar, S., Dodd, A., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13747 · Cited by 7
Self-citation
Multiplexed glycan immunofluorescence identification of pancreatic cancer cell subpopulations in both tumor and blood samples
Binkowski, B., Klamer, Z. L., Gao, C., Staal, B., Repesh, A., Tran, H.-L., Brass, D. M., Bartlett, P., Gallinger, S., Blomqvist, M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt0029 · Cited by 6
Self-citation
The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtyping in Pancreatic Cancer
Guenther, M., Surendran, S. A., Steinke, L., Liou, I., Palm, M. A., Heinemann, V., Haas, M., Boeck, S. H., & Ormanns, S. (2025) · Biomolecules · doi:10.3390/biom15030426 · Cited by 8
Precision Medicine and Pancreatic Cancer
George, B. (2021) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2021.06.008 · Cited by 6
Stabilization of the classical phenotype upon integration of pancreatic cancer cells into the duodenal epithelium
Bozóky, B., Moro, C. F., Strell, C., Geyer, N., Heuchel, R. L., Löhr, M. J., Ernberg, I. T., Székely, L., Gerling, M., & Bozóky, B. (2021) · Neoplasia · doi:10.1016/j.neo.2021.11.007 · Cited by 6
Integrative transcriptomic analysis identifies a novel gene signature to predict prognosis of pancreatic cancer in different subtypes
Li, C. Y., Rajapakshe, K., & Maitra, A. (2022) · Pancreatology · doi:10.1016/j.pan.2022.08.007 · Cited by 6
Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?
Khakoo, S. S., Petrillo, A., Salati, M., Muhith, A., Evangelista, J., Seghezzi, S., Petrelli, F., Tomasello, G., & Ghidini, M. (2021) · Cancers · doi:10.3390/cancers13174396 · Cited by 6
Kinome state is predictive of cell viability in pancreatic cancer tumor and stroma cell linesPreprint
Berginski, M. E., Jenner, M. R., Joisa, C. U., Hererra, S. G., Golitz, B. T., Lipner, M. B., Leary, J. R., Rashid, N. U., Johnson, G. L., Yeh, J. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.21.451515 · Cited by 6
Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making
Theocharopoulos, C., Machairas, N., Ziogas, I. A., Mungo, B., Chiaro, M. D., Glantzounis, G. K., Schulick, R. D., & Sotiropoulos, G. C. (2025) · Cancers · doi:10.3390/cancers18010094 · Cited by 5
Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here
May, M. S., Park, W., & O'Reilly, E. M. (2026) · Drugs · doi:10.1007/s40265-026-02295-0 · Cited by 4
Updates in Molecular Profiling of Pancreatic Ductal Adenocarcinoma
Lee, J. J., & Yeh, J. J. (2024) · Surgical Clinics of North America · doi:10.1016/j.suc.2024.04.001 · Cited by 5
Blocking GATA6 Alleviates Pyroptosis and Inhibits Abdominal Wall Endometriosis Lesion Growth Through Inactivating the PI3K/AKT Pathway
Du, X., Yang, H., Kang, X., Fu, C., & Yang, T. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01583-4 · Cited by 6
Therapeutic targets in the pancreatic adenocarcinoma microenvironment: past challenges and opportunities for the future
Tsang, E. S., & Tempero, M. A. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.22 · Cited by 5

Authors: O’Kane, G. M., Grünwald, B. T., Jang, G.-H., Masoomian, M., Picardo, S., Grant, R. C., Denroche, R. E., Zhang, A., Wang, Y., Miller, J. K., Lam, B., Krzyzanowski, P. M., Lungu, I. M., Bartlett, J. M. S., Peralta, M., Vyas, F., Khokha, R., Biagi, J., Chadwick, D., Ramotar, S., Hutchinson, S., Dodd, A., Wilson, J. M., Notta, F., Zogopoulos, G., Gallinger, S., Knox, J. J., & Fischer, S. E.
Affiliations: 1Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Ontario Institute for Cancer Research (CA)
University Health Network (CA)
Research Institute of the McGill University Health Centre (CA)
Kingston General Hospital (CA)
ORCID: Grünwald, Barbara T.
Jang, Gun-Ho
Grant, Robert C.
Denroche, Robert E.
Zhang, Amy
Wang, Yifan
Miller, Jessica K.
Lam, Bernard
Krzyzanowski, Paul M.
Lungu, Ilinca M.
Bartlett, John M.S.
Peralta, Melanie
Vyas, Foram
Khokha, Rama
Biagi, James
Ramotar, Stephanie
Hutchinson, Shawn
Dodd, Anna
Wilson, Julie M.
Notta, Faiyaz
Zogopoulos, George
Knox, Jennifer J.
Fischer, Sandra E.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2020-03-10
Volume: 26
Issue: 18
Pages: 4901-4910
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-19-3724
OpenAlex: W3011562658
Semantic Scholar: d72ef3593540c2afcd56ffaaa1ecbdf174cca98b
Cited by: 352
References: 39
Citations by year: 2026: 54 · 2025: 58 · 2024: 58 · 2023: 60 · 2022: 48 · 2021: 56 · 2020: 16
FWCI: 16.25
Type: journal article
Language: en
Update notices: correction (2022-06-13)
Open access: green
www.research.ed.ac.uk
Licence: other-oa
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Funders: Princess Margaret Cancer Foundation (ALTF 116-2018, DEU 1199182 FLF-P)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords: GATA6, pancreatic ductal adenocarcinoma, basal-like subtype, classical subtype, cancer subtyping, chemoresistance, modified FOLFIRINOX, overall survival, prognostic factors, keratin 5, tumor hypoxia, COMPASS trial
MeSH terms: Irinotecan, Oxaliplatin, RNA-Seq, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Pancreatic Neoplasms, Prognosis, Prospective Studies, Multicenter Studies as Topic, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal, GATA6 Transcription Factor, Response Evaluation Criteria in Solid Tumors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks